Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perry M Elliott

Showing results (151-160 of 292) with videos related to

Pageof 30
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriersPhilip M Croon, Marion van Vugt, Cornelis P Allaart, et al.
BMC Medicine|July 14, 2025
Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriersPhilip M Croon, Marion van Vugt, Cornelis P Allaart, et al.
European Journal of Heart Failure|March 4, 2026
The Yield and Clinical Impact of Genetic Testing in Older Patients with Dilated CardiomyopathyDouglas E Cannie, Athanasios Bakalakos, Petros Syrris, et al.
JACC. Heart Failure|August 23, 2025
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated CardiomyopathyDouglas E Cannie, Athanasios Bakalakos, Petros Syrris, et al.
Open Heart|February 17, 2025
Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy/Myocarditis Registry of the EURObservational Research Programme of the European Society of CardiologyKatarzyna Mizia-Stec, Juan R Gimeno, Philippe Charron, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 3, 2023
A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-makingNathan Green, Yang Chen, Constantinos O'Mahony, et al.
Circulation. Genomic and Precision Medicine|May 13, 2020
Cryptic Splice-Altering Variants in <i>MYBPC3</i> Are a Prevalent Cause of Hypertrophic CardiomyopathyLuis R Lopes, Pedro Barbosa, Mario Torrado, et al.
JAMA Cardiology|August 28, 2024
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank PopulationNay Aung, Hannah L Nicholls, C Anwar A Chahal, et al.
Circulation. Heart Failure|July 21, 2023
Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized MedicineEmanuele Monda, Athanasios Bakalakos, Marta Rubino, et al.
European Heart Journal|October 16, 2013
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)Constantinos O'Mahony, Fatima Jichi, Menelaos Pavlou, et al.
Pageof 30

Showing results (151-160 of 292) with videos related to

Sort By:
Pageof 30
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriersPhilip M Croon, Marion van Vugt, Cornelis P Allaart, et al.
BMC Medicine|July 14, 2025
Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriersPhilip M Croon, Marion van Vugt, Cornelis P Allaart, et al.
European Journal of Heart Failure|March 4, 2026
The Yield and Clinical Impact of Genetic Testing in Older Patients with Dilated CardiomyopathyDouglas E Cannie, Athanasios Bakalakos, Petros Syrris, et al.
JACC. Heart Failure|August 23, 2025
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated CardiomyopathyDouglas E Cannie, Athanasios Bakalakos, Petros Syrris, et al.
Open Heart|February 17, 2025
Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy/Myocarditis Registry of the EURObservational Research Programme of the European Society of CardiologyKatarzyna Mizia-Stec, Juan R Gimeno, Philippe Charron, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 3, 2023
A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-makingNathan Green, Yang Chen, Constantinos O'Mahony, et al.
Circulation. Genomic and Precision Medicine|May 13, 2020
Cryptic Splice-Altering Variants in <i>MYBPC3</i> Are a Prevalent Cause of Hypertrophic CardiomyopathyLuis R Lopes, Pedro Barbosa, Mario Torrado, et al.
JAMA Cardiology|August 28, 2024
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank PopulationNay Aung, Hannah L Nicholls, C Anwar A Chahal, et al.
Circulation. Heart Failure|July 21, 2023
Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized MedicineEmanuele Monda, Athanasios Bakalakos, Marta Rubino, et al.
European Heart Journal|October 16, 2013
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)Constantinos O'Mahony, Fatima Jichi, Menelaos Pavlou, et al.
Pageof 30